The thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple behavioural claim: negative headline shocks are overreacted to and tend to revert toward fundamentals. It buys names hit by sentiment below -0.4 that are already technically oversold — RSI14 under 35 and trading below their 20-day SMA — and sizes into the fall. Exits are equally mechanical: reversion (RSI14 above 50 or a reclaim of the SMA20), with a hard stop on fresh lows under continued negativity, treated as a genuine fundamental break rather than noise.
The design leans on recent sentiment-asymmetry literature (arXiv:2509.11970 and corroborating work on stock-level investor sentiment). Requiring both a sentiment shock and price-defined oversold conditions is a sensible guard against catching falling knives on headlines alone.
Validation
This is where PanicFade earns attention. Across four walk-forward folds spanning 2021–2026, every fold was positive (+1.6%, +3.88%, +10.14%, +21.7%), with out-of-sample return of 21.7% and an OOS Sharpe of 2.44. The Probabilistic Sharpe Ratio sits at 0.985, and — importantly — the Deflated Sharpe Ratio, which penalises the 27 trials run during development, still comes in at 0.56. Surviving deflation at all is more than many strategies manage.
That said, read the folds carefully. Performance is heavily concentrated in the most recent window: fold 1 returned just 1.6% at a Sharpe of 0.19, and the headline 2.44 Sharpe belongs to a single 2025–2026 fold. Full-sample Sharpe is a plainer 0.955, and CAGR over 1,233 days is only 6.79%. The strategy is validated and consistent, but not a high-octane compounder — its 37.93% total return took roughly three and a half years.
Recent activity
Here the picture is quiet to the point of dormancy. The only recent fill was a 10-share WMT buy at $103.12 on 28 August. Every scheduled run since — six sessions from 3 to 10 September — executed nothing and rejected nothing. Cash has held flat at $8,958.54 against a total near $10,016, meaning roughly 89% of the book is idle, waiting for a qualifying panic that simply hasn't appeared in this calm tape. Total equity has drifted down marginally over the window (from ~$10,045 to ~$10,016).
Balance sheet on the strategy
Strengths: a coherent, literature-grounded thesis; conjunctive entry filters that avoid pure headline-chasing; four-for-four positive folds; a shallow 9.3% max drawdown and a 62.88% win rate.
Risks: returns are regime-concentrated, so the flattering OOS Sharpe may not persist; full-sample Sharpe is sub-1; turnover is very high at 5,807%; and by construction the strategy sits in cash for long stretches, creating meaningful opportunity cost in trending, low-panic markets like the present one. PanicFade v4 looks like a well-disciplined satellite allocation — not a core engine.